AstraZeneca's new pill has demonstrated significant effectiveness in lowering blood pressure in patients who struggle with conventional treatments, according to results from a late-stage clinical trial. The trial showed that the pill not only met its primary endpoint but also improved patient outcomes significantly. This development could offer a new therapeutic option for those with hard-to-treat hypertension.

AstraZeneca has entered an AI-driven research agreement with China's CSPC Pharmaceutical Group, potentially worth up to $5.3 billion, aimed at developing therapies for chronic diseases. This partnership follows previous collaborations and reflects AstraZeneca's strategy to enhance its presence in China's pharmaceutical market.